India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,028 M Sivakumaran ₹2,600 Cr
Revenue · FY 2025
₹8.94 Lakh
▼ 98% YoY
Net loss · FY 2025
₹5.48 Cr
Latest filing
EBITDA · FY 2025
-₹19.62 Lakh
EBITDA margin -219.5%
Authorised capital
₹47.5 Cr
Registered with MCA
Paid-up capital
₹47.15 Cr
Issued & subscribed
Satisfied charges
₹1.18 Cr
No open charges
Company age
18 yrs
Est. 2008
Directors on board
5
As per MCA filings
About Tergene Biotech Limited
Data last updated:
Tergene Biotech Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Aurobindo Pharma Ltd. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 07 March 2008 and has been in existence for over 18 years.
Its director M Sivakumaran is #1,028 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24230TG2008PLC113178. Its GSTIN is 36AACCT8939J1ZR (Telangana).
The company has an authorised share capital of ₹47.5 Cr and a paid-up capital of ₹47.15 Cr. It was formerly known as Tergene Biotech Private Limited. It is led by directors including Umesh Krishnamoorthy and Mosuvan Kuppusamy.
Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Galaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032.
As per the financials filed for FY 2025, the company reported a revenue of ₹8.94 Lakh, a decline of 98% compared to the previous year. For the same year it recorded a net loss of ₹5.48 Cr and EBITDA of -₹19.62 Lakh (EBITDA margin -219.5%). Revenue has declined at a compounded annual rate (CAGR) of 69% over three years and 46% over five years.
The company is associated with 2 brands: Aurobindo Pharma and Tergene Biotech. As per MCA filings, the company has satisfied charges of ₹1.18 Cr on record. The company has 10 deals on record (7 funding rounds, 2 rights issues, 1 secondary share transfer), with disclosed funding of ₹17.72 Cr; the latest was in September 2018. The company has 3 MSME Form 1 returns on record between 2019 and 2022, listing 10 overdue payments to 3 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website tergene.com.
Company details
CIN U24230TG2008PLC113178
Registration Number 113178
Incorporation Date 07 March 2008
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 22 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Aurobindo Pharma Ltd
Compliance Status Active Compliant
CIN history
Tergene Biotech has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24230TG2008PLC113178, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230TG2008PLC113178 | Current |
| U24230TN2008PTC066737 | Previous |
| U24230TG2008PTC113178 | Previous |
Key People
Umesh Krishnamoorthy Director Mosuvan Kuppusamy Director Sivakumaran Meenakshisunderam Director Recognitions & Rankings of Tergene Biotech
Contact details
Tergene Biotech Limited's registered office is in Hyderabad, Telangana. Its website is tergene.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressGalaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032
- IndustryLife Sciences, Biotechnology
To see the full contact details of Tergene Biotech Limited, buy the company report.
Comprehensive company report
Tergene Biotech Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Tergene Biotech operates two associated brands: Aurobindo Pharma and Tergene Biotech. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Generic biocatalytic solutions are provided for pharmaceutical applications. | aurobindo.com | |
| Bio-conjugate technologies for bacterial vaccines and conjugates are developed. | tergene.com |
Business activity
The main business activity of Tergene Biotech is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Tergene Biotech Limited, buy the company report.
Financials of Tergene Biotech Limited
FY 2025 filings availableTergene Biotech Limited reported revenue of ₹8.94 Lakh (down 98% YoY) for FY 2025.
Revenue · FY 2025
₹8.94 Lakh ▼ 98%
Net loss · FY 2025
₹5.48 Cr
EBITDA · FY 2025
-₹19.62 Lakh margin -219.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 98%
3 years · compounded
▼ 69%
5 years · compounded
▼ 46%
EBITDA CAGR growth
1 year
▲ 88%
3 years · compounded
▲ 59%
5 years · compounded
▲ 36%
Revenue has declined at a compounded annual rate (CAGR) of 46% over five years, including a 98% fall in the latest year. EBITDA rose 88% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹19.62 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹5.48 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -219.5% | ||||
| Net Profit Margin | |||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Tergene Biotech Limited, buy the company report.
Board of directors of Tergene Biotech Limited
Tergene Biotech has 5 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Umesh Krishnamoorthy | Director | 28 Jun 2023 | 3 Years 4 Months | Current |
| Mosuvan Kuppusamy | Director | 07 Mar 2008 | 18 Years 7 Months | Current |
| Sivakumaran Meenakshisunderam Also directs: Curateq Biologics Private Limited, Auro Peptides Limited, Apl Healthcare Limited and 2 more | Director | 01 Apr 2015 | 11 Years 7 Months | Current |
| Kuppusamy Sathyan Also directs: Samies Technologies Private Limited | Director | 07 Mar 2008 | 18 Years 7 Months | Current |
| Santhanam Subramanian Also directs: Eugia Steriles Private Limited, Engenra Biologics Private Limited, Avogent Lifesciences Private Limited and 5 more | Director | 26 Aug 2016 | 10 Years 2 Months | Current |
Auditor
Tergene Biotech Limited is audited by G P M & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| G P M & Associates | FY 2023 | 015343S |
Shareholding
The shareholding of Tergene Biotech Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Tergene Biotech Limited, buy the company report.
Charges & borrowings
Open charges
None
Satisfied charges
₹1.18 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Aug 2012 | 10373010 | Biotechnology Industry Research Assistance Council | ₹1.18 Cr | Satisfied |
To see the full charge records of Tergene Biotech Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Tergene Biotech Limited has 10 deals on record (7 funding rounds, 2 rights issues, 1 secondary share transfer), with disclosed funding of ₹17.72 Cr; the latest was in September 2018.
Total deals
10
Funding rounds
7
Rights issues
2
Secondary share transfer
1
Disclosed funding
₹17.72 Cr
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2017 | Rights issue | ₹5.65 Cr | Investors: Aurobindo Pharma Ltd |
| Dec 2014 | Rights issue | ₹3.62 Cr | Investors: Aurobindo Pharma Ltd , 2 individuals |
| Dec 2013 | Funding round | ₹46.5 Lakh | Investors: an individual |
| Apr 2013 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2012 | Funding round | ₹92.4 Lakh | Investors: 3 individuals |
To see the full deal history of Tergene Biotech Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Tergene Biotech Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Tergene Biotech Limited has 3 MSME Form 1 returns on record between 2019 and 2022, listing 10 overdue payments to 3 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (3 of 3)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| CBCC Global Research LLP | |||
| Indian Cash and Carry Private Limited |
To see the full MSME payment records of Tergene Biotech Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Tergene Biotech has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AACCT8939J1ZR | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Tergene Biotech Limited, buy the company report.
Recent activity
Tergene Biotech Limited has 15 board changes on record since 2008: 5 appointments and 10 cessations. The latest: Umesh Krishnamoorthy ceased to be Additional Director on 20 Aug 2023.
AGM
Tergene Biotech Limited last Annual general meeting of members was held on 22 Sep 2025 as per latest MCA records.
Filing
Tergene Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Ceased
Umesh Krishnamoorthy ceased to be Additional Director.
Appointed
Umesh Krishnamoorthy was appointed as Director.
Ceased
Satakarni Makkapati ceased to be Additional Director.
Charges
A charge registered on 30 Aug 2012 via Charge ID 10373010 with Biotechnology Industry Research Assistance Council was fully satisfied on 15 Nov 2021.
Ceased
Sarath Chandra Reddy Penaka ceased to be Director.
Ceased
Santhanam Subramanian ceased to be Additional Director.
Appointed
Santhanam Subramanian was appointed as Director.
Ceased
Jayant Shrikant Karajgi ceased to be Director.
Ceased
Sivakumaran Meenakshisunderam ceased to be Additional Director.
Ceased
Kuppusamy Sathyan ceased to be Director.
9 earlier events are in the company report.
Frequently asked questions
Tergene Biotech is an active public limited company based in Hyderabad, Telangana, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 07 March 2008 (18+ years old) and is registered under CIN U24230TG2008PLC113178.
Tergene Biotech has 5 current directors:
- Umesh Krishnamoorthy - Director
- Mosuvan Kuppusamy - Director
- Sivakumaran Meenakshisunderam - Director
- Kuppusamy Sathyan - Director
- Santhanam Subramanian - Director
The latest financial statements of Tergene Biotech on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 22 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Tergene Biotech is 36AACCT8939J1ZR, registered in Telangana.
The CIN (Corporate Identification Number) of Tergene Biotech is U24230TG2008PLC113178. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Tergene Biotech was incorporated on 07 March 2008, making it 18+ years old. It is registered with the Registrar of Companies, Hyderabad.
Tergene Biotech has 10 deals on record (7 funding rounds, 2 rights issues, 1 secondary share transfer), with disclosed funding of ₹17.72 Cr; the latest was in September 2018.
Umesh Krishnamoorthy ceased to be Additional Director on 20 Aug 2023. Umesh Krishnamoorthy was appointed as Director on 28 Jun 2023. Satakarni Makkapati ceased to be Additional Director on 25 Jul 2022. Tergene Biotech has 15 board changes on record in total.
Tergene Biotech has 3 MSME Form 1 returns on record between 2019 and 2022, listing 10 overdue payments to 3 micro and small suppliers. The latest return was filed on 28 Apr 2022.
Tergene Biotech can be reached through the website tergene.com. Its registered office is in Hyderabad, Telangana, India.
The registered office of Tergene Biotech is at Galaxy Floors 22 – 24 Plot No. 1 Survey No. 831 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages